drugset / Trial / NCT03069911
Trial of OnabotulinumtoxinA for Depression in Parkinson Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study evaluates the efficacy of onabotulinumtoxinA (BOTOX®) in the treatment of depression associated with Idiopathic Parkinson Disease in adults. As a Randomized Controlled Trial, half of the participants will receive onabotulinumtoxinA injections and half will receive a placebo saline solution.
Timeline
- Start
- 2018-11-01
- Primary completion
- 2019-05-30
- Completion
- 2019-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 29 iu | Intramuscular |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 40 iu | Intramuscular |